There is one clinical trial.
The purpose of this trial is to investigate the efficacy and safety of continuous intravenous administration of low dose iloprost versus placebo for 72-hours, in 80 patients with COVID-19 suffering from respiratory failure. The study hypothesis is that iloprost may be beneficial as an endothelial rescue treatment as it is anticipated to deactivate the endothelium and restore vascular integrity in COVID-19 patients suffering from respiratory failure caused by endothelial breakdown, ultimately improving survival. Given that the pulmonary system, apart from the brain, is the most highly vascularized vital organ in the body, extensive endothelial damage is a central feature of acute respiratory distress syndrome (ARDS) with respiratory failure being the rationale for the current study COMBAT-COVID-19.
Description: Days alive without mechanical ventilation in the ICU within 28 daysMeasure: Mechanical ventilation free days Time: Until ICU discharge, maximun 28 days after randomization
Description: Vital status of the patient at day 28 and day 90Measure: 28 and 90-day mortality Time: Day 28 and 90 after randomization
Description: Mean daily modified SOFA score in the intensive care unit (scores for each of five systems range from 0 to 4, with higher scores indicating more severe dysfunction; range score 0-20).Measure: Modified Sequential Organ Failure Assessment (SOFA) Time: Until ICU discharge, maximun 90 days after randomization
Description: Days alive without vasopressor in the ICU within 28-and 90 daysMeasure: Vasopressor free days Time: Until ICU discharge, maximun 90 days after randomization
Description: Days without renal replacement in the ICU within 28 -and 90 daysMeasure: Renal replacement free days Time: Until ICU discharge, maximun 90 days after randomization
Description: Days alive without mechanical ventilation in the ICU within 90 daysMeasure: Mechanical ventilation free days Time: Until ICU discharge, maximun 90 days after randomization
Description: Numbers of serious adverse reactions within the first 7 daysMeasure: Serious adverse reactions (SARs) Time: Until day 7 after randomization
Description: Numbers of serious adverse events within the first 7 daysMeasure: Serious adverse events (SAEs) Time: Until day 7 after randomization
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports